Highlights the indolent but progressive nature of alveolar soft part sarcoma and the potential of novel targeted therapies based on a 19-year combined treatment experience of two patients.
Multimodal therapy may prolong control in metastatic ASPS; leaves open optimal sequencing and prospective trials of targeted agents.
BACKGROUND: Alveolar soft part sarcoma is a rare soft tissue sarcoma that is characterized by a pattern of slow growth with metastases to the lung, bone, and brain that is not responsive to conventional cytotoxic chemotherapy. OBSERVATIONS: We describe 2 patients, with a combined 19 years of treatment experience including multiple different chemotherapeutic and targeted therapy regimens, surgery, and radiotherapy. We also present a review of the literature regarding treatment options to highlight recent findings. CONCLUSIONS: Alveolar soft part sarcoma is an indolent, but persistently progressive disease. Novel therapeutic agents hold promise in its management.
No takes yet. Share an insight, caveat, or question.
Kuo et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: